#### **ORIGINAL ARTICLE**



# **An in‑depth assessment of diabetes‑related lower extremity amputation rates 2000–2013 delivered by twenty‑one countries for the data collection 2015 of the Organization for Economic Cooperation and Development (OECD)**

**Fabrizio Carinci1,2 · Luigi Uccioli3 · Massimo Massi Benedetti4 · Nicolaas Sieds Klazinga5,6**

Received: 5 July 2019 / Accepted: 12 September 2019 / Published online: 11 October 2019 © Springer-Verlag Italia S.r.l., part of Springer Nature 2019

### **Abstract**

**Background** International comparisons of diabetes-related lower extremity amputation rates are still hampered by diferent criteria used for data collection and analysis. We aimed to evaluate trends and variation of major/minor amputations, using agreed defnitions adopted by the Organization for Economic Cooperation and Development in 2015.

**Methods** Direct age–sex standardized rates were calculated per 100,000 subjects per year between 2000 and 2013, using major/minor amputations with diabetes diagnosis as numerators and the total population or number of people with diabetes as denominators. Longitudinal trends were investigated using generalized estimating equations.

**Results** Twenty-one countries reported major amputations referred to the general population, showing a mean reduction from 10.8 to 7.5 per 100,000 (−30.6%). Eleven countries also reported major amputations among people with diabetes, showing a mean reduction from 182.9 to 128.3 per 100,000 (−29.8%). Minor amputations remained stable over the study period. Longitudinal trends showed a signifcant average annual decrease of −0.19 per 100,000 in the general population (95% CI −0.36 to −0.02; *p*=.03) and −4.52 per 100,000 among subjects with diabetes (95% CI −6.09 to −2.94; *p*<.001). The coefficient of variation of major amputation rates between countries was fairly high  $(64\%$ —in the total population,  $67\%$ among people with diabetes).

**Conclusions** The study highlighted a clinically signifcant reduction of major amputations, in both the general population and among people with diabetes. The use of standardized defnitions, while increasing the comparability of multinational data, highlighted remarkable diferences between countries. These results can help identifying and sharing best practices efectively on a global scale.

**Keywords** Lower extremity amputations in diabetes · Healthcare Quality Indicators · Diabetes care · Health systems performance assessment · Generalized estimating equations

Managed By Massimo Porta.

*Disclaimer* This is an independent report of aggregate data made directly available by the OECD to the authors. We did not request formal permission to publish contents of the manuscript from the OECD or Member countries. The opinions expressed in this article are those of the authors alone; not those of the OECD, nor of its Member countries.

**Electronic supplementary material** The online version of this article [\(https://doi.org/10.1007/s00592-019-01423-5\)](https://doi.org/10.1007/s00592-019-01423-5) contains supplementary material, which is available to authorized users.

 $\boxtimes$  Fabrizio Carinci fabrizio.carinci@unibo.it

Extended author information available on the last page of the article

### **Introduction**

The effectiveness of healthcare interventions should be routinely monitored using indicators that can be practically used to improve performance [[1\]](#page-8-0).

Lower extremity amputations represent a major threat for people with diabetes, due to the associated burden and increased risk of a fatal outcome [\[2](#page-8-1)]. Preventive strategies include targeted interventions to reduce the odds of amputations through better metabolic control and systematic foot care at an early stage of the disease [\[3](#page-9-0)].

Targeted indicators can provide meaningful clinical advise on how diabetes care aligns with expected targets,

e.g. major and minor amputations [[4](#page-9-1)]. These can occur for diferent reasons (the minor to salvage the limb, the major to save the patient) and should be interpreted accordingly.

The Organization for Economic Cooperation and Development (OECD) has been collecting lower extremity amputation rates in diabetes (LEARD) from national governments since 2006 [\[5,](#page-9-2) [6](#page-9-3)]. Every 2 years, the OECD requests participating countries the entire time series from 2000 onward, using a well-specifed protocol that is revised over time based on activity on feld. Data gathered include the number of amputations and total population per year by sex and age bands.

So far, the number of countries adopting LEARD for national reporting appears to be substantially lower compared to other performance indicators [[7](#page-9-4)]. A potential explanation can be found in the critical limitations highlighted for the OECD data collection 2013 [[4](#page-9-1)].

According to the defnitions therein applied, duplications were possible as repeated counts of amputations in the same subject were all included in the numerator. This refected the fact that in many countries, following individuals over time is not feasible, due to the unavailability of a unique personal identifer (UPI) or the restrictions imposed by data protection regulations [[8](#page-9-5), [9\]](#page-9-6).

Moreover, there was no clear indication on the use of registries and poor coverage of non-ICD9 coding. Finally and most importantly, the clinical rationale was weak, as the exclusion criteria were too limited and minor and major lower extremity amputations were not diferentiated.

To improve the reporting of LEARD, an international group of experts agreed to revise and use new defnitions for the OECD data collection 2015.

In this paper, we use the resulting database to respond to the following research questions:

- How do countries compare in terms of major and minor LEARD?
- What are the long terms trends highlighted by the new time series 2000–2013?
- Which are the main country-level factors affecting the heterogeneity of results?

The following sections report the main fndings of our investigation.

### **Materials and methods**

The analysis was conducted using materials produced in various preparatory steps of the OECD data collection 2015, summarized in the following subsections.

### **Background materials and revised standardized defnitions of LEARD**

Revised standardized defnitions of LEARD for 2015 were produced by national representatives of the OECD expert group of Healthcare Quality Indicators (HCQI), coordinated by the Italian Ministry of Health in collaboration with the Italian National Agency for Regional Health Services (AGENAS) and the EUBIROD network of diabetes registers ([http://www.eubirod.eu\)](http://www.eubirod.eu).

An exploratory survey of data sources and algorithms for the calculation of LEARD was conducted by volunteering governmental organizations of Ireland, Israel, Italy, Latvia, Norway and Slovenia between July–September 2014. Responses covered aspects of data linkage, standardized defnitions, reporting, availability of a UPI and presence of diabetes registers.

A set of twenty reports were collected to provide a background on the topic, of which nineteen were extracted from PubMed/Google Scholar using "lower", "amputation", "diabetes" and "indicator" as search keywords over the timeframe 2009–2014, plus the operating manual used for the OECD data collection 2013.

A draft set of defnitions prepared in consultation with partners of the EUBIROD network was tested on the Italian National Database of hospital discharges, 2002–2013.

All results were collected in a fnal report [\[10\]](#page-9-7) that was distributed as background material at the second annual HCQI meeting 2014. The proposed criteria were presented by the OECD Secretariat to the Expert Group, which voted for their adoption in the data collection 2015 (see Table [1\)](#page-2-0) [[11](#page-9-8)].

#### **Data collection process**

Standardized definitions were provided to designated governmental organizations involved with the OECD data collection 2015, which processed national databases using their own internal resources and local facilities. The OECD secretariat sent an empty formatted Excel sheet to representatives of 36 Member States and associated countries involved in the HCQI project  $[11]$  $[11]$ , to be returned duly flled between January and May 2015. Countries were requested to specify the total number of subjects per numerator and denominator by sex and age bands for all years between 2000 and 2013.

Additional contextual data (see Table [2\)](#page-3-0) were added to explore the association of LEARD with fundamental health systems characteristics (funding mechanism) and data collection procedures (use of a registry to collect amputations, ICD-9 derived coding).

#### <span id="page-2-0"></span>**Table 1** Standardized defnitions applied for the OECD data collection of amputation rates 2015



#### **Statistical analysis**

The authors of the present paper were given direct access to all Excel worksheets returned to the OECD, soon after the publication of Health at a Glance 2015 [[11](#page-9-8)].

Different indicators were calculated using the data available, based upon the different definitions of numerators (number of major and minor amputations) and denominators (total population and people with diabetes). The impact of multiple amputations over the same subject was evaluated through "patient-based estimates", calculated using the most severe amputation observed in each year for the same subject (see Table [1](#page-2-0)). Although figures were available for all age–sex classes, LEARD

<span id="page-3-0"></span>**Table 2** OECD countries reporting data for this study and their health system characteristics



Coding: T: funding mechanism=tax-based (Y/N); R: source=registry  $(Y/N)$ ; C:  $coding=ICD9$  derived (1), ICD10 derived (2), or Other (3). Source: OECD Health System Characteristics Survey 2012

were calculated only for subjects aged 15 or over, due to the very low number of events recorded at early ages.

Statistical analysis included the calculation of crude and direct age–sex standardized rates per 100,000 subjects for all definitions, by country and year. The pooled population from all participating countries at year 2013 or last year available was used as the standard.

Descriptive measures were used to respond to the first research question regarding the most current international comparisons of LEARD, including: measures of centrality (mean, median, range) and dispersion (coefficient of variation  $\times$  100, CV).

Graphical outputs included histograms of amputation rates by country and boxplots superimposed to turnip charts to display results over time [[12\]](#page-9-9). In both cases, an average line representing the OECD arithmetic mean value of data points for each year is added to the graph.

All data points used for graphical outputs refer to the value recorded each year or for the last year available.

#### **Multivariate modelling**

Linear and Poisson multivariate models using Generalized Estimating Equations (GEE) were carried out to address the second and third research questions.

The GEE models were used to ensure robust confdence intervals for correlated values within countries (exchangeable structure) [[13\]](#page-9-10). This method allowed deriving estimates of annual changes based on the entire time series, thus not excluding countries presenting any missing values for specifc years in the timeframe.

Linear models allowed estimating the average annual change in LEARD, taking into account the main countrylevel characteristics that might have infuenced the data collection process. Poisson models were applied to estimate the average increase/decrease in incidence of LEARD due to country-level factors (public vs. private fnancing, data derived from diabetes registry, ICD vs. non-ICD coding classifcation), independently from average annual change over time and composition of the population by age and sex.

Results of multivariate models were expressed as point estimates and 95% confdence intervals. For linear models, estimates reported changes in amputation rates per 100,000 subjects, per unit increase of each covariate (upper vs. lower class of age; named category vs. complementary, e.g. males vs. females). For Poisson models, estimates were reported as incidence rate ratios (IRR), i.e. increased/decreased incidence per unit increase of each covariate (as above).

Sensitivity analysis was carried out to test relevant changes in parameter estimates of regression models: a) by excluding selected covariates; and b) by comparing results obtained splitting the sample of observations in two separate time frames: up to year 2007 and 2007–2013.

All analyses were performed using the R statistical language  $[14]$  $[14]$  $[14]$ .

### **Results**

#### **Response rates and data coverage**

A total of 21 (58%) countries delivered data for the study.

The timeframe was not evenly covered, with most countries reporting from 2007 on. The last year available was 2013 for 15 (42%) countries, 2012 for New Zealand, Switzerland and Luxembourg (8%) and 2011 for Belgium and The Netherlands (6%).

All participants delivered data on major amputations and total population at least for 1 year, by sex and age bands. Among them, 16 (44%) countries reported also minor amputations.

A subset of 11 (31%) countries delivered the total number of people with diabetes by sex and age bands, allowing the calculation of crude overall diabetes prevalence rates for 2013 or last year available (median: 7.2, range: 5.7–9.4) and the indicator using people with diabetes in the denominator.

Age–sex standardized rates for all defnitions and the entire timeframe are included in Tables A1 and A2 in the Appendix (supplementary data).

#### **International comparisons for last year available**

Results obtained for year 2013 (or last year available) are displayed in Fig. [1](#page-4-0).

The mean value (range) of major amputations was equal to 7.5 per 100,000 (1.2–17.6) and 128.3 per 100,000 (27.9–282.7) when referred to the total population and people with diabetes, respectively. The mean age–sex standardized rate of minor amputations was equal to 11.1 per 100,000  $(1.2-32.1)$  in the total population and 184.3 per 100,000 (22.1–422.6) among people with diabetes, respectively.

In general, higher LEARD for all indicators were noted for Israel, Germany and Slovenia. On the other hand, Sweden, Italy, Korea and Luxembourg showed systematically lower LEARD.

The coefficient of variation between countries seemed fairly high (ranging between 64 and 67% for major and 82–87% for minor amputations in the total population and among people with diabetes, respectively).

#### **Longitudinal trends**

Longitudinal trends over 2000–2013 are shown in Fig. [2](#page-5-0).

Overall, major amputations appeared to be decreasing over time, with the exception of 2008 and 2013. Trends were generally consistent across countries, with stronger declines (>25%) observed for Israel, Italy, Luxembourg, New Zealand and Sweden. Minor amputations appeared generally stable until 2008; then, they started to increase. Trends are clearer when using people with diabetes in the denominator.

#### **Impact of re‑amputations**

According to data delivered by seven countries (see Fig. [3\)](#page-5-1), age–sex standardized rates of major amputations showed to be 17.5% higher on average than patient-based estimates, meaning that an equivalent portion can be attributed to re-amputations. The diference appeared to be higher for Sweden  $(+74%)$  and Italy  $(+32%)$ , with all others falling below 9%.

The decreasing trend of LEARD was more clearly defned when using the patient-based method.



<span id="page-4-0"></span>Fig. 1 Lower extremity amputation rates in diabetes according to different definitions, year 2013 or last year available, OECD data collection 2015



<span id="page-5-0"></span>**Fig. 2** Trends of lower extremity amputation rates in diabetes according to diferent defnitions, year 2000–2013, OECD data collection 2015



<span id="page-5-1"></span>**Fig. 3** Lower extremity major amputation rates in diabetes according to the patient-based estimate, OECD data collection 2015

### **Multivariate analysis**

The results of GEE multivariate regression are included in Table [3.](#page-6-0)

Linear models (upper section, Model 1) confrmed a signifcant annual reduction of major amputations in the total population (− 0.19 per 100,000; 95% CI − 0.36 to −0.02 per 100,000) as well as among people with diabetes

<span id="page-6-0"></span>**Table 3** Results of multivariate modelling of lower extremity amputations in diabetes (generalized estimating equations), OECD 2000–2013

Variable	Minor						Major				
	People with diabetes		Total population			People with diabetes			Total population		
Linear regression <sup>a</sup>											
	Estimate (95% CI)	P > Z		Estimate (95% CI) $P > Z$			Estimate (95% CI)	P > Z	Estimate (95% CI)	P > Z	
Model $1$ $(All)^b$											
Average year change	$-1.96(-4.02, 0.11)$	0.06		$0.12(-0.07, 0.31)$	0.23		$-4.52(-6.09,-2.94)$		$< 0.001 - 0.19(-0.36, -0.02)$	0.03	
Model 2 (Tax-based)											
Average year change	$-1.09(-2.63, 0.46)$	0.17		0.17(0.08, 0.26)					$< 0.001 -3.56 (-5.08, -2.05) < 0.001 -0.09 (-0.13, -0.05)$	< 0.001	
Model 3 (Insurance-based)											
Average year change	$-1.88(-4.43, 0.67)$ 0.15			$0.13(-0.18, 0.44)$	0.41				$-5.43(-6.87, -3.99)$ < 0.001 $-0.25(-0.51, 0.01)$	0.06	
Poisson regression <sup>c</sup>											
		IRR (95% CI)	$P > \chi^2$	IRR (95% CI)		$P > \chi^2$	IRR (95% CI)	$P > \chi^2$	IRR (95% CI)	$P > \chi^2$	
Model 4 (All)											
Age		1.20(1.06, 1.35)	< 0.01	1.87(1.81, 1.94)		< 0.001	1.46(1.36, 1.56)	< 0.001	2.05(1.94, 2.16)	< 0.001	
Males		3.05(2.71, 3.43)	< 0.001	3.51(3.03, 4.07)		< 0.001	2.20(2.06, 2.35)	< 0.001	2.48(2.23, 2.76)	< 0.001	
Insurance-based		2.42(1.08, 5.45)	0.03	2.99(1.69, 5.28)		< 0.001	2.03(1.17, 3.54)	0.01	1.86(1.05, 3.28)	0.03	
Registry		2.36(2.00, 2.78)	< 0.001	1.07(0.75, 1.52)		0.70	2.12(1.94, 2.32)	< 0.001	0.92(0.57, 1.50)	0.75	
Coding: non-ICD9/derived		0.20(0.11, 0.36)	< 0.001	0.36(0.25, 0.53)		< 0.001	0.17(0.15, 0.20)	< 0.001	0.51(0.31, 0.85)	0.01	
Average year change		1.00(0.98, 1.02)	0.810	1.02(1.01, 1.04)		0.01	0.96(0.95, 0.98)	< 0.001	0.99(0.97, 1.00)	0.03	

Statistically significant results ( $P < .05$ ) are presented in bold

*Source*: OECD Health System Characteristics Survey 2012, Healthcare Quality Indicators 2015

*IRR* incidence rate ratio

a Outcome: age–sex standardized rates

<sup>b</sup>Covariates: financing, registry, coding (coefficients not shown)

c Outcome: number of lower amputations

(−4.52 per 100,000; −6.09 to −2.94 per 100,000). Minor amputations did not change signifcantly in either case.

Separate analyses by fnancing mechanism showed variable results.

Systems with tax-based financing (Model 2) slightly increased their rates of minor amputations in the total population over time (0.17 per 100,000; 0.08–0.26 per 100,000), while major amputations in the total population  $(-0.09$  per 100,000; −0.13 to −0.05 per 100,000) and among people with diabetes  $(-3.56$  per  $100,000$ ;  $-5.08$  to  $-2.05$  per 100,000) decreased.

Systems with insurance-based financing (Model 3) reduced the rates of major amputations among people with diabetes  $(-5.43 \text{ per } 100,000, -6.87 \text{ to } -3.99 \text{ per } 100,000)$ .

Poisson models (lower section) showed a significant 4% annual reduction in the incidence of major amputations among people with diabetes  $(IRR = 0.96, 0.95-0.98)$ and a 1% reduction for the total population (IRR =  $0.99$ ; 0.97–1.00). The incidence of minor amputations increased by 2% in the total population only (IRR = 1.02; 1.01–1.04).

Increased incidence of major amputations (among people with diabetes; total population) was signifcantly associated with age progression (IRR = 1.46, 1.36–1.56; 2.05, 1.94–2.16), being male (IRR = 2.20, 2.06–2.35; 2.48, 2.23–2.76), having an insurance-based fnancing mechanism (IRR=2.03, 1.17–3.54; 1.86, 1.05–3.28) and using a diabetes registry as data source (IRR = 2.12, 1.94–2.32; 0.92, 0.57–1.50 NS). On the other hand, non-ICD9 coding systems had a signifcant lower chance of capturing cases both in the total population and among people with diabetes (IRR =  $0.17$ ,  $0.15-0.20$ ;  $0.51$ ,  $0.31-0.85$ ). The incidence of minor amputations showed similar patterns, with an increased number of cases among males and insurancebased systems.

Sensitivity analyses did not show substantial changes. In fact, diferent combinations of selected covariates did not alter either the annual changes or incidence rate ratios, while longitudinal trends did not show diferent patterns of adjusted annual changes up to and after 2007.

#### **Discussion**

The OECD data collection 2015 gathered a unique database of lower extremity major and minor amputations in diabetes from 21 countries of diferent parts of the world. To the best of our knowledge, this is the frst investigation presenting a coherent approach for the collection of LEARD internationally from official sources. A rapid search of articles published between 2014 and 2018 found only national studies, with the exception of one review referred to diferent time frames, data collection methods and national objectives [\[15](#page-9-12)].

In 2013 (or last year available), the average rates of major amputations due to diabetes were equal to 7.5 per 100,000 when referred to the total population and 128.3 per 100,000 when referred to people with diabetes.

In specific countries, age–sex standardized rates of major amputations among people with diabetes were substantially higher than average. Specifc cases of concern are those of Germany (132.2 per 100,000), Israel (158.7 per 100,000), Portugal (188.1 per 100,000) and Slovenia (282.7 per 100,000). These four countries alone account for over one third  $(N=10,801)$  of all major amputations in the total sample. On the other hand, much lower rates were noted for Italy (49.4 per 100,000), Luxembourg (48.4 per 100,000) and Korea (27.8 per 100,000).

In 2013 (or last year available), the average rates of minor amputations due to diabetes were equal to 11.1 per 100,000 when referred to the total population and 184.3 per 100,000 when referred to people with diabetes. The cases of Slovenia (411.6 per 100,000) and Germany (422.6 per 100,000) are those outstanding in terms of minor amputations among people with diabetes.

Compared to previous reports [[4](#page-9-1)], the use of distinct definitions for major and minor amputations increased the accuracy of the data reported. In particular, given that major amputations are performed in hospital settings where data registration is more accurate, the reported rates are not biased by the uncertain number of minor amputations, which are more easily carried out in outpatient settings where data recording can be less accurate.

Computing major amputation rates using people with diabetes in the denominator is also more appropriate than using the total population.

Firstly, because it allows a proper evaluation of amputation risk using the correct reference population.

Secondly, because it cannot be biased by an increased diabetes prevalence. In fact, any reduction in rates occurred when more people with diabetes are diagnosed would be obscured if referred to the general population.

Overall, we found that 21 OECD countries experienced a signifcant average annual decrease of major amputations over 14 years regardless of the method of calculation.

The result shows good progress overall, consistently with a recent review of national reports [[15](#page-9-12)]. However, the pace of improvement does not seem to guarantee a sharp decline of major amputations long term.

Multivariate Poisson models showed that, after adjusting by age, sex and average annual change, the incidence of both major and minor amputations in countries with insurancebased payments is double compared to that of national health systems.

This result confrms the fndings of our previous analysis [[4\]](#page-9-1) for which precise explanations are still missing.

Can this relate to a more uniform and complete coverage of people with diabetes or to specifc service arrangements?

Italy is a case in point: can the positive results be attributed to health system characteristics (e.g. fnancing system, universal coverage and decentralization) or to the specifc organization of care for diabetes (comprehensive care and multiprofessional/multidisciplinary teams for diabetic foot management, coordinated by a diabetologist across three different levels of intervention). How much can be explained by individual lifestyles and personal characteristics? These questions require more granular data on the provision of care to be investigated with the required level of detail.

The impact of diabetes registries and classifcation systems on data accuracy highlights the importance of strengthening the information infrastructure. Efective strategies to overcome limitations in data accuracy include the intensive use of national databases  $[16]$  $[16]$ , targeted surveys, e.g. the UK National Diabetes Audit [[17\]](#page-9-14) or the US NHIS [[18](#page-9-15)], claims for selected populations, e.g. US Medicare [[19](#page-9-16)], pay for performance schemes, e.g. the UK Quality and Outcomes Framework [[20](#page-9-17)], computerized linked registries, e.g. the Finnish linkage of exemptions with A10 codes for pharmaceutical drugs and hospital discharges [\[21](#page-9-18)] and, above all, population-based registries, e.g. the DARTS in Scotland [[22\]](#page-9-19) and the Swedish Diabetes National Quality Register [\[23\]](#page-9-20).

Improved data systems will allow using more accurate defnitions that can allow international comparisons based on sound methods, e.g. life course analysis [\[24](#page-9-21)] and amputation-free risk-adjusted survival analysis [\[25\]](#page-9-22). In this perspective, the routine calculation of patient-based estimates should be encouraged further, as it can help the evaluation of outcomes in terms of person-centred care. Our data show that only few countries were able to deliver LEARD using a UPI. The high variation of estimates of re-amputations seems to suggest that in most cases the national information infrastructure may be still inadequate to support personbased comparisons.

Following the data collection 2015, the new defnitions were officially endorsed to produce "Health at a Glance"  $[11, 10]$  $[11, 10]$ [26](#page-9-23)], the fagship OECD publication that further encouraged building national surveillance systems for the production of more accurate indicators [\[27](#page-9-24)].

International collaborations, e.g. the EUBIROD network can help leverage standards [[28](#page-9-25), [29](#page-9-26)] and improve the comparability of LEARD across health systems. Automating the process of data collection using common tools can help improving statistical reporting to support continuous benchmarking of diabetes care in ways that are not currently available [[30\]](#page-9-27).

Finally, key limitations of our study are worth to be outlined.

Firstly, we could not check directly how data were processed in each country. Diferent interpretations of the operating manual and software procedures may have afected data collection. However, the OECD secretariat continuously checked for consistency and any update of data sheets was taken into account for the production of this paper.

Secondly, the criterion applied for diabetes diagnosis may have not been unique. While diagnosis at the time of amputation was based on criteria applied at each episode (or before, if diagnosis was recovered from previous records), prevalence rates were requested altogether to countries in 2015. Since prevalence was estimated locally (using periodic surveys, computerized records, etc.), we could not ascertain whether numerators and denominators used the same criterion in each year.

Thirdly, the analysis was mainly based on country-level factors, with the exception of age and sex classes. This makes results prone to the ecological fallacy, meaning that we could not control for imbalances in other individual risk factors that might have altered estimates.

Fourthly, the association found for fnancing systems can only be interpreted as a composite proxy of a mix of system level characteristics, whose individual contribution cannot be ascertained with the data currently available.

Finally, and most importantly, given the lack of relevant clinical characteristics available, risk-adjusted models could not assess the impact of patient case-mix on amputation rates, which obviously limit the epidemiological interpretation of the associations found.

### **Conclusions**

The rates of major amputations in OECD countries signifcantly decreased over fourteen years.

The use of standardized defnitions, while increasing the comparability of multinational data, also showed remarkable diferences between countries.

The results of this study can help fostering the ability to monitor diabetes-related amputations through a continuous improvement of coding practices and the repeated application of analytical models.

**Acknowledgements** The conduction of this study has been made possible through in kind support ofered by the Italian Ministry of Health, represented by F. Carle, Director of Office VI, Directorate of Health Policy and Planning, in collaboration with the Italian Agency for Regional Health Services (AGENAS). The new OECD standardized defnitions applied in this paper have been delivered with the active contribution of the following members of the EUBIROD network: Jana Lepiksone (Centre for Disease Control, Latvia); Karianne Fjeld Loovas (Noklus, Norway), Scott Cunningham, (University of Dundee, Scotland); Zeliko Metelko (CrodiabNet, University of Zagreb, Croatia); Tamara Poljicanin (National Institute of Public Health, Croatia); Joseph Azzopardi (University of Malta, Malta); Przemka Jarosz-Chobot (Medical University of Silesia, Poland); Iztok Stotl (University of Ljubljana, Slovenia). The following members of the HCQI Expert Group participated to the targeted OECD R&D Study: Deirdre Mulholland and Grainne Cosgrove (Department of Health, Ireland); Yael Applbaum and Ziona Haklai (Ministry of Health, Israel); Hanne Narvulbold (Directorate of Health, Norway) and Veena Raleigh (The King's Fund, England). The authors are particularly grateful to Ian Brownwood and Nelly Biondi from the OECD Health Division, for their continuous assistance with issues related to the OECD data collection.

**Author's contribution** FC, LU, MMB and NSK conceived and designed this study. FC designed the statistical analysis and analysed the data. FC, LU, MMB and NSK interpreted the results. FC wrote the frst draft of the manuscript. FC, LU, MMB and NSK contributed to the writing of the manuscript. FC, LU, MMB and NSK agreed with the results and conclusions of the manuscript. All authors have read and confrmed that they met ICMJE criteria for authorship. All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. FC is the guarantor. We attest that we have obtained appropriate permissions and paid any required fees for use of copyright protected materials.

**Data and resource availability** The datasets generated during and/or analysed during the current study are not publicly available as they are held by the OECD as an integral part of their statutory activity of international data collection. Any request for access should be directly submitted to the OECD Health Division.

#### **Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no confict of interests.

**Human and animal rights** This article does not contain any studies with human or animal subjects performed by the any of the authors.

**Informed consent** All persons gave their informed consent prior to the inclusion in the study.

### **References**

- <span id="page-8-0"></span>1. Carinci F, Van Gool K, Mainz J et al (2015) Towards actionable international comparisons of health system performance: expert revision of the OECD framework and quality indicators. Int J Qual Health Care 27:137–146. <https://doi.org/10.1093/intqhc/mzv004>
- <span id="page-8-1"></span>2. Stern JR, Wong CK, Yerovinkina M et al (2017) A meta-analysis of long-term mortality and associated risk factors following lower extremity amputation. Ann Vasc Surg 42:322–327
- <span id="page-9-0"></span>3. Hofmann M, Kujath P, Flemming A et al (2015) Survival of diabetes patients with major amputation is comparable to malignant disease. Diabetes Vasc Dis Res 12:265–271
- <span id="page-9-1"></span>4. Carinci F, Massi Benedetti M, Klazinga NS, Uccioli L (2016) Lower extremity amputation rates in people with diabetes as an indicator of health systems performance. A critical appraisal of the data collection 2000–2011 by the Organization for Economic Cooperation and Development (OECD). Acta Diabetol 53(5):825–832
- <span id="page-9-2"></span>5. Nicolucci A, Greenfeld S, Mattke S (2006) Selecting indicators for the quality of diabetes care at the health systems level in OECD countries. Int J Qual Health Care 18(Suppl 1):26–30
- <span id="page-9-3"></span>6. Forde I, Morgan D, Klazinga NS (2013) Resolving the challenges in the international comparison of health systems: the must do's and the trade-ofs. Health Policy 112(1–2):4–8
- <span id="page-9-4"></span>7. Rotar AM, van den Berg MJ, Kringos DS, Klazinga NS (2016) Reporting and use of the OECD Health Care Quality Indicators at national and regional level in 15 countries. Int J Qual Health Care 28(3):398–404.<https://doi.org/10.1093/intqhc/mzw027>
- <span id="page-9-5"></span>8. Carinci F, Di Iorio CT, Ricciardi W, Klazinga N, Verschuuren M (2011) Revision of the European Data Protection Directive: opportunity or threat for public health monitoring? Eur J Public Health 21(6):684–685
- <span id="page-9-6"></span>9. Di Iorio CT, Carinci F, Oderkirk J (2014) Health Research and Systems' Governance are at risk: Should the right to data protection override health? J Med Ethics 40(7):488–492
- <span id="page-9-7"></span>10. Carinci F, Massi Benedetti M, Uccioli L et al (2014) Standardized defnition and calculation of lower extremity amputation rates in diabetes for the OECD Health Care Quality Indicators project. Room document. In: 2nd OECD annual meeting of the HCQI
- <span id="page-9-8"></span>11. OECD (2015) Health at a Glance 2015: OECD Indicators. OECD Publishing. [https://www.oecd-ilibrary.org/social-issues-migration](https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2015_health_glance-2015-en)[health/health-at-a-glance-2015\\_health\\_glance-2015-en](https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2015_health_glance-2015-en). Accessed 06/01/2018
- <span id="page-9-9"></span>12. Carinci F, Di Stanislao F, Moirano F, Ceccolini C, Carle F, Bevere F (2014) Italy: geographic variations in health care. In: Geographic variations in health care: What do we know and what can be done to improve health system performance? OECD. [http://](http://www.keepeek.com/Digital-Asset-Management/oecd/social-issues-migration-health/geographic-variations-in-health-care_9789264216594-en#page287) [www.keepeek.com/Digital-Asset-Management/oecd/social-issue](http://www.keepeek.com/Digital-Asset-Management/oecd/social-issues-migration-health/geographic-variations-in-health-care_9789264216594-en#page287) [s-migration-health/geographic-variations-in-health-care\\_97892](http://www.keepeek.com/Digital-Asset-Management/oecd/social-issues-migration-health/geographic-variations-in-health-care_9789264216594-en#page287) [64216594-en#page287.](http://www.keepeek.com/Digital-Asset-Management/oecd/social-issues-migration-health/geographic-variations-in-health-care_9789264216594-en#page287) Accessed 06/01/2018
- <span id="page-9-10"></span>13. Nicolucci A, Carinci F, Graepel J, Hohman T, Ferris R, Lachin JM (1996) The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy: a meta-analysis of individual patient data. Diabetes Care 10:1091–1096
- <span id="page-9-11"></span>14. R Development Core Team (2005) A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. <http://www.R-project.org>. Accessed 06/01/2018
- <span id="page-9-12"></span>15. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW (2019) Global trends in diabetes complications: a review of current evidence. Diabetologia 62(1):3–16
- <span id="page-9-13"></span>16. Lombardo FL, Maggini M, De Bellis A, Seghieri G, Anichini R (2014) Lower extremity amputations in persons with and without diabetes in Italy: 2001–2010. PLoS ONE 9(1). [https://journ](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0086405) [als.plos.org/plosone/article?id=10.1371/journal.pone.0086405](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0086405). Accessed 23 Sept 2019
- <span id="page-9-14"></span>17. Jeffcoate W, Young B, Holman N (2012) The variation in incidence of amputation throughout England. Pract Diabetes 29(5):205–207a
- <span id="page-9-15"></span>18. Li Y, Burrows NR, Gregg EW, Albright A, Geiss LS (2012) Declining rates of hospitalization for nontraumatic lower-extremity amputation in the diabetic population aged 40 years or older: U.S., 1988–2008. Diabetes Care 35(2):273–277
- <span id="page-9-16"></span>19. Margolis DJ, Hoffstad O, Nafash J et al (2011) Location, location, location: geographic clustering of lower-extremity amputation among Medicare benefciaries with diabetes. Diabetes Care 34(11):2363–2367
- <span id="page-9-17"></span>20. Vamos EP, Bottle A, Majeed A, Millett C (2010) Trends in lower extremity amputations in people with and without diabetes in England, 1996–2005. Diabetes Res Clin Pract 87(2):275–282
- <span id="page-9-18"></span>21. Winell K, Venermo M, Ikonen T, Sund R (2013) Indicators for comparing the incidence of diabetic amputations: a nationwide population-based register study. Eur J Vasc Endovasc Surg 46(5):569–574
- <span id="page-9-19"></span>22. Kennon B, Leese GP, Cochrane L et al (2012) Reduced incidence of lower-extremity amputations in people with diabetes in Scotland: a nationwide study. Diabetes Care 35(12):2588–2590
- <span id="page-9-20"></span>23. Peterson A, Gudbjörnsdottir S, Löfgren UB et al (2015) Collaboratively improving diabetes care in Sweden using a national quality register: successes and challenges—a case study. Qual Manag Health Care 24(4):212–221
- <span id="page-9-21"></span>24. von Bonsdorff MB, von Bonsdorff ME, Haanpää M et al (2018) Work-loss years among people diagnosed with diabetes: a reappraisal from a life course perspective. Acta Diabetol 55(5):485–491
- <span id="page-9-22"></span>25. Jefcoate WJ, Vileikyte L, Boyko EJ, Armstrong DG, Boulton AJM (2018) Current challenges and opportunities in the prevention and management of diabetic foot ulcers. Diabetes Care 41(4):645–652
- <span id="page-9-23"></span>26. OECD (2013) Health at a Glance 2017: OECD Indicators. OECD Publishing. [https://www.oecd-ilibrary.org/social-issues-migration](https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2017_health_glance-2017-en)[health/health-at-a-glance-2017\\_health\\_glance-2017-en](https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2017_health_glance-2017-en). Accessed 06/01/2018
- <span id="page-9-24"></span>27. Teti A, Gabrys L, Ziese T et al (2017) Proceedings of the international workshop 'Development of a National Diabetes Surveillance System in Germany: Core Indicators and Conceptual Framework', Berlin, Germany, 11–12/7 2016. BMC Proc. 11(Suppl 3):3
- <span id="page-9-25"></span>28. Di Iorio CT, Carinci F, Brillante M et al (2013) Cross-border flow of health information: Is "privacy by design" enough? Privacy performance assessment in EUBIROD. Eur J Public Health 23(2):247–253
- <span id="page-9-26"></span>29. Cunningham SG, Carinci F, Brillante M et al (2016) Defning a European diabetes data dictionary for clinical audit and healthcare delivery: core standards of the EUBIROD project. Methods Inf Med 55(2):166–176
- <span id="page-9-27"></span>30. Carinci F (2015) Essential levels of health information in Europe: an action plan for a coherent and sustainable infrastructure. 22. Health Policy 119(4):530–538

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional afliations.

## **Afliations**

### **Fabrizio Carinci1,2 · Luigi Uccioli3 · Massimo Massi Benedetti4 · Nicolaas Sieds Klazinga5,6**

- <sup>1</sup> Department of Statistical Sciences, University of Bologna, Via Belle Arti 41, 40126 Bologna, Italy
- <sup>2</sup> National Agency for Regional Health Services (AGENAS), Via Puglie 23, 00187 Rome, Italy
- <sup>3</sup> Department of Systems Medicine, Università Tor Vergata, Rome, Italy
- <sup>4</sup> Hub for International Health ReSearch (HIRS), Perugia, Italy
- <sup>5</sup> Health Division, Organisation for Economic Co-operation and Development (OECD), Paris, France
- <sup>6</sup> Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands